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ABSTRACT
Objectives The congenital pulmonary airway malformation volume ratio (CVR) is a widely used sonographic measure
of relative mass size in fetuses with lung malformations. The purposes of this study were to examine serial CVR
measurements to understand longitudinal growth patterns and to determine correlation with postnatal imaging.
Methods An institutional review board-approved retrospective review was performed on fetuses referred for an
echogenic lung malformation between 2002 and 2014. For each fetus, the CVR was prospectively calculated using 2D
ultrasound and followed with advancing gestation.
Results Based on 40 fetuses, the mean initial CVR was 0.51 ± 0.07 at 20.5 ± 0.3weeks of gestation. The CVR increased
after 24weeks of gestation (p = 0.0014), peaking at a CVR of 0.96 ± 0.11 at 25.5 ± 0.05weeks, followed by a significant
decrease in the CVR to 0.43 ± 0.07 prior to term (p< 0.0001). However, approximately one third showed no appreciable
increase in size. The mean CVR was significantly correlated with postnatal chest computed tomography (CT) size
dimensions (p = 0.0032) and likelihood for lung resection (p = 0.0055).
Conclusions Fetal lung malformations tend to follow one of two distinct growth patterns, characterized by either (1) a
maximal CVR between 25 and 26weeks of gestation or (2) minimal change in relative growth. The mean CVR
correlates with postnatal CT size and operative management. © 2015 John Wiley & Sons, Ltd.
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INTRODUCTION
Over the last two decades, echogenic fetal lung malformations,
which include congenital pulmonary airway malformations
(CPAM) and bronchopulmonary sequestrations (BPS), have
been diagnosed with greater frequency by ultrasound.1 Based
on a recent study, the current incidence of lung malformations
may be as high as one in 2000 to 2500 live births.2 The
increased rate of detection is thought to be secondary to the
widespread use of fetal ultrasound screening as well as ongoing
improvements in the sensitivity of the anatomic survey,
thereby resulting in the detection of smaller masses that do
not cause mass effect.3 As a result, the risk of hydrops in fetuses
with lung malformations is now lower than previously
reported,4,5 and perinatal survival rates exceeding 95% are
the norm.3,6,7
Previous work has shown that the congenital pulmonary
airway malformation volume ratio (CVR), as measured by
two-dimensional (2D) ultrasound, is a simple, useful way to
assess relative mass volume and is an independent predictor
of perinatal outcome in fetal lung malformations.3,8 To date,
however, relative mass volume as a function of gestational
age has not been well studied.9–11 In one report, initial size
progression followed by regression occurs in approximately
one third of all lesions.12 A study from the Children’s Hospital
of Philadelphia subsequently had similar findings based on both
mass volume and CVR data and suggested a plateau in growth
between 26 and 28weeks of gestation.13 Unfortunately, these
data were based on a sampling of different time points
from different patients and not from serially following
individual patients.14 Other studies from multiple centers
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have suggested that lung malformations may have markedly
different growth patterns, ranging from significant increases
in size throughout gestation, resulting in hydrops and need
for fetal intervention,9,13,15 to spontaneous regression without
growth in most lesions.6,10,16
In this study, we examined serial ultrasound data to
determine the extent to which fetal lung malformations change
in size throughout gestation. We hypothesized that the relative
size of lung malformations, as measured by the CVR, might
have predictable variation based on gestational age, which
therefore has implications on prenatal management and
postnatal outcome.
METHODS
This Health Insurance Portability and Accountability Act-
compliant study was approved by the University of Michigan
Institutional Review Board (#51132). The medical records of
consecutive fetuses referred for management of a lung
malformation between January 2002 and March 2014 were
retrospectively reviewed. Cases were ascertained from a
prospectively maintained database at the Fetal Diagnosis
and Treatment Center, a tertiary care referral center with
comprehensive fetal intervention capabilities based at the
C.S. Mott Children’s and Von Voigtlander Women’s Hospital,
University of Michigan Health System. For a subset of
these patients (n = 21), detailed sonographic data on lung
malformations in relationship to respiratory morbidity have
been previously reported.3
All fetuses underwent serial 2D sonograms (Phillips iU-22,
Andover, MA, USA; General Electric Voluson 730, Waukesha,
WI, USA; or ATL HDI 2000, Seattle, WA, USA) performed by
a staff maternal-fetal medicine specialist. In each case, the
presence of a systemic vascular supply to the lung lesion
was assessed by color and power Doppler ultrasound.
Fetal hydrops was defined as the presence of fluid in two or
more spaces, including ascites, pleural effusion, pericardial
effusion, or subcutaneous edema, usually with supporting
echocardiographic evidence of cardiac dysfunction.17,18
The three-dimensional size of an echogenic lesion was
prospectively measured (in cm) to calculate a CVR as
originally described by Crombleholme and colleagues.13
Briefly, the CVR was obtained by taking the product of the
length, width, and depth of the mass, multiplying by a 0.523
correction factor (assuming its shape as a prolate ellipse),
and then dividing by the head circumference to normalize
for gestational age. In an effort to minimize any potential
intra-operator and inter-operator variability over time, the
maximal height of the lesion was first measured in the sagittal
plane followed by measurement in the plane perpendicular
to this axis. During the study period, the recommended
frequency of subsequent ultrasound exams was not standardized
but generally ranged between 1 and 4weeks based on the most
recent CVR measurement and the presence of hydrops.
Given the study goal of examining fetal lung lesion growth
over time, fetuses had to satisfy specific inclusion criteria for
further analysis of growth patterns, namely, at least one CVR
measurement before 24.0 weeks with two or more subsequent
scans between 24.0 weeks and delivery. Relative changes
in the CVR over time were normalized based on the initial
CVR (CVR0). CVR measurements were also stratified based
on early (<24.0 weeks), middle (24.0–29.0 weeks), and late
(>29.0 weeks) gestation. Prenatal variables were analyzed
and correlated with outcomes data. After 2009, maternal
betamethasone was routinely given for microcystic lesions
with CVRs greater than 1.6 with polyhydramnios or with any
signs of hydrops or cardiac dysfunction based on data
reported elsewhere.14
Postnatal assessment of lung malformations was performed
by arterial phase contrast-enhanced chest computed
tomography (CT) using either a 16 or 64 multi-detector
scanner (GE Healthcare, Waukesha, WI, USA), in most cases
electively between 2 and 4months of age.19 Mass volume
was measured by maximum size in three dimensions
(anteroposterior, craniocaudal, and transverse) based on
axial and multi-planar reconstructed images interpreted by
board-certified, fellowship-trained pediatric radiologists, all
of whom were blinded to prenatal studies, using a picture
achieving and communication system workstation (Horizon
Rad Workstation 11.9, McKesson, San Francisco, CA, USA).
Operative resection was based on individual pediatric
surgeon preference and parental concerns but was generally
recommended for symptomatic lesions, macrocystic disease,
asymptomatic microcystic CPAMs measuring greater than
2 cm in size, and asymptomatic intralobar masses associated
with a systemic arterial vessel.20
All values were reported as the mean ± standard error of
the mean unless otherwise indicated. Statistical analyses
were performed by the Wilcoxon matched-pairs signed rank
test, repeated measures one-way analysis of variance,
Mann–Whitney test, Spearman correlation, or second-degree
polynomial regression analyses as appropriate using Prism




One hundred referrals for a fetal lung malformation
were identified during the study period. The serial CVR
measurements for these patients are shown in Figure 1. The
mean CVR for the entire group was 0.72 ± 0.08 [median: 0.50,
interquartile range (IQR): 0.26–0.86]. There were 56 left-sided
and 43 right-sided cases. One patient had bilateral lesions. A
systemic feeding vessel arising from the thoracoabdominal
aorta was identified in 23 fetuses. Twenty-six lesions were
macrocystic, and 62 were associated with mediastinal shift
on the initial scan.
Table 1 reveals the ultrasound characteristics of lesions
based on whether inclusion criteria were met for longitudinal
analysis. Among the 40 patients that met the inclusion
criteria, the mean number of ultrasounds was 6.15 ± 0.37
(median: 5.5, IQR: 4.0–8.0). All had unilateral disease,
composed of 21 (52.5%) left-sided and 19 (47.5%) right-sided
masses. Thirty-three (82.5%) lesions were microcystic,
and seven (17.5%) were macrocystic. Twenty-three (57.5%)
had associated mediastinal mass effect on initial exam.
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Eleven (27.5%) had a systemic feeding vessel. Three (7.5%)
had concomitant extrapulmonary anomalies, including
hydronephrosis (n = 2) and complex heart defect (n = 1). The
CVR0 was 0.51 ± 0.07 (median: 0.31, IQR: 0.19–0.64). None of
these patients had a CVR0 greater than 1.6. The mean CVR
was 0.61 ± 0.07 (median: 0.5, IQR: 0.27–0.86).
Table 1 shows that, compared with fetuses excluded from
the study, those included had a significantly greater number
of ultrasound scans (p< 0.0001) and were diagnosed at an
earlier gestational age (p< 0.0001). However, there were no
significant differences based on laterality (p = 0.42), presence
of a systemic feeding vessel (p = 0.47), microcystic appearance
(p = 0.11), mediastinal shift (p = 0.40), CVR0 (p = 0.08),
maximum CVR greater than 1.6 (p = 1.00), and mean CVR
(p = 0.87). Whereas none of the included fetuses developed
hydrops, four (6.7%) in the excluded group developed hydrops.
Because of small sample size, the difference in the rate of
hydrops between the groups failed to meet statistical
significance (p = 0.15).
Maternal betamethasone was administered to five included
(13%) and five excluded (8%) patients (p=0.52). All fetuses
meeting inclusion criteria responded satisfactorily to corti-
costeroids as shown by a reduction in the maximum CVR of
2.14±0.29 at 25.1 ±0.55weeks to a final CVR (mean, 1.16±0.17 at
31.9 ±4.4weeks). Although there were no fetal lung resections or
thoracoamniotic shunts performed in either group, three excluded
fetuses underwent ex utero intrapartum treatment-to-resection
compared with none in the included group (p=0.27).
Longitudinal growth patterns
The CVR measurements for all patients meeting the inclusion
criteria are shown in Figure 2A. The mean CVR0 was 0.51
± 0.07 at 20.5 ± 0.3 weeks of gestation (median weeks: 20.1,
IQR: 19.6–21.9), and the mean final CVR was 0.41 ± 0.07
at 33.6 ± 0.5 weeks of gestation (median weeks: 33.7, IQR:
31.1–36.3). There was no significant difference in the CVR0
compared with the final CVR (p = 0.098).
The mean maximum CVR was 0.96 ± 0.11, which occurred
at a mean of 25.5 ± 0.05 weeks of gestation (median weeks:
25.2, IQR: 23.5–27.2). Based on statistical modeling of serial
CVR data using second-degree polynomial regression analysis
(R2 = 0.1, Figure 2B), the CVR peaks at 0.85 ± 0.1 at 26.1 weeks.
However, there was growth variability among different
malformations that was captured by two distinct growth
profiles. Based on data normalized by the CVR0, the first
group consisted of a small subset of malformations (n = 13,
32.5%) that either had minimal relative enlargement (0–50%
Table 1 Prenatal characteristics of lung malformations
Variable
Adequate longitudinal ultrasound data?
Yes (n = 40) No (n = 60) p
Number of ultrasounds 6.2 ± 0.37 2.7 ± 0.25 <0.0001
Gestational age at initial scan, weeks 20.5 ± 0.28 26.1 ± 0.64 <0.0001
Left sided, n (%) 21 (53) 36 (61) 0.42
Systemic feeder vessel, n (%) 11 (28) 12 (20) 0.47
Microcystic, n (%) 33 (83) 40 (67) 0.11
Mediastinal shift, n (%) 23 (58) 40 (67) 0.40
Hydrops, n (%) 0 (0) 4 (7) 0.15
CVR at initial scan 0.51 ± 0.07 0.73 ± 0.11 0.13
Maximum CVR> 1.6, n (%) 7 (18) 11 (18) 1.00
Mean CVR 0.61 ± 0.07 0.80 ± 0.14 0.87
Other major anomalies, n (%) 3 (8) 4 (7) 1.00
Maternal betamethasone, n (%) 5 (13) 5 (8) 0.52
Fetal interventions, n (%) 0 (0) 0 (0) 1.00
CVR, congenital pulmonary airway malformation volume ratio.
*p< 0.05.
Figure 1 Line graph of serial congenital pulmonary airway
malformation volume ratio (CVR) measurements in fetal lung
malformations (n = 100). Each line represents the CVR measurements
for an individual fetus throughout pregnancy
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increase) or a relative decrease in size throughout gestation
(Figure 2C). The second group consisted of a larger subset of
lesions (n = 27, 67.5%) that tended to enlarge (>50% size
increase) between 24 and 29weeks, after which a marked
reduction in the CVR was observed up to the time of delivery
(Figure 2D). This escalation followed by spontaneous
regression in the CVR persisted even after exclusion of growth
profiles that may have been altered by exposure to maternal
betamethasone (n = 5).
After stratification of data points based on early, middle,
and late gestational age cohorts, there was a significant
increase from the CVR0 (0.51 ± 0.07) compared with the
middle gestation CVR (0.74 ± 0.09, p = 0.0014, Figure 3A).
Further univariate analysis based on various prenatal
sonographic characteristics, including suspected CPAM,
presence of a systemic feeding vessel, and microcystic
disease, also revealed a significant tendency towards an
increase in absolute CVR measurements between 24 and
29weeks of gestation (Figure 3B–C).
In all fetuses followed longitudinally, the peak malformation
growth between 24 and 29weeks of gestation was followed by
a significant decrease in the absolute CVR to 0.43 ± 0.07
(Figure 3A, p< 0.0001). Statistical significance with respect
to the observed size progression and subsequent regression
of these malformations was maintained after exclusion of
maternal betamethasone patients (p = 0.02 and p< 0.0001,
respectively).
Correlation with postnatal outcome
There were no cases of intrauterine demise. Gestational age
at delivery was 38.9 ± 0.28weeks (median weeks: 39.1, IQR:
38.7–39.9). Two (5%) fetuses, both with maximum CVRs greater
than 2.0 after 29weeks of gestation, had respiratory distress at
birth and were managed with ventilator support and lobectomy
in the neonatal period. There were no postnatal deaths.
Based on review of all postnatal chest CT scan reports
obtained at our institution (n= 35), 32 (91.4%) children had an
identifiable parenchymal abnormality of the lung consistent
with their prenatal diagnosis. Three (8.6%) had completely
normal CT scans. The mean lesion maximum diameter was
2.71 ± 0.28 cm. The initial, mean, maximum, and final CVRs
were significantly correlated with postnatal CT size dimensions
Figure 2 Serial congenital pulmonary airway malformation volume ratio (CVR) measurements of fetal lung malformations with adequate
longitudinal follow-up data. (A) Line graph of CVR data (n = 40 lesions). (B) Statistical modeling of CVR data using second-degree
polynomial regression analysis (solid curve) with 95% confidence intervals (dotted curves). (C) Line graph depicting lack of relative CVR growth
is a subgroup (n = 13) of lung lesions. Y-axis shows CVR data normalized by the initial CVR (CVR0). (D) Line graph depicting increased relative
CVR growth before 30weeks gestation in a subgroup (n = 27) of lung lesions. Y-axis shows CVR data normalized by the CVR0
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(in cm) based on linear regression analyses (p= 0.0016, <0.0001,
0.0002, and 0.0034, respectively). Of all CVR measurements, the
mean CVR for a given fetus was the most significant and
showed the strongest correlation with postnatal size by CT
imaging (r = 0.66, Figure 4A).
Lung resection was performed in 26 (65%) children at
6.4 ± 0.67months of age (median months: 6.0, IQR: 4.9–8.0).
Pathological evaluation of specimens revealed that nine (34.6%)
were CPAMs, five (19.2%) were BPS, and nine (34.6%) were
hybrid lesions with features of both CPAM and BPS. Other
pathology included a bronchogenic cyst in combination with
congenital lobar emphysema (n=1, 3.8%) and segmental
emphysema/bronchial atresia (n=2, 7.7%). The mean CVR was
significantly associated with an increased likelihood of postnatal
lung surgery (Figure 4B, p=0.0011). Among those undergoing
surgical resection, the mean CVR was 0.80± 0.10. Among those
managed non-operatively, the mean CVR was 0.33 ±0.06.
DISCUSSION
In this study, we used the CVR to evaluate the ultrasound
growth patterns of prenatal lung masses using a large,
prospectively collected database. Much like the lung–head
ratio,21 an ultrasound-derived parameter used to predict
outcomes in fetal congenital diaphragmatic hernia, our group
hypothesized that the relative size of lung malformations, as
measured by the CVR, may be variable depending on the
gestational age and therefore has implications for prenatal
management and postnatal outcome. Using a systematic
Figure 3 Box plots with whiskers from minimum to maximum representing absolute congenital pulmonary airway malformation volume ratio
(CVR) data stratified by gestational age categories (the symbol ‘*’ denotes p< 0.05 compared with other groups). (A) All lung malformations
measured before 24weeks, between 24 and 29weeks, and after 29weeks of gestation. (B) Prenatal congenital pulmonary airway
malformations (CPAM) masses measured before 24weeks compared with 24–29weeks of gestation. (C) Prenatal masses with a systemic
feeder vessel measured before 24weeks compared with 24–29weeks of gestation. (D) Prenatal microcystic masses measured before 24weeks
compared with 24–29weeks of gestation
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approach that excluded late referrals and those with minimal
follow-up, we found that the majority of malformations do
not exhibit erratic growth. Instead, approximately two thirds
of all lung lesions follow a predictable change in the CVR
during the second trimester characterized by a modest but
predictable increase in size following initial diagnosis. In
these cases, the CVR tended to peak from 25 to 26weeks of
gestation. An approximately twofold increase in the CVR
was seen in most lesions. This increase was consistent
regardless of other sonographic features, including prenatal
CPAM diagnosis, presence of a systemic feeding vessel, or
microcystic appearance. On the other hand, roughly one
third of lesions did not follow this anticipated growth profile
and instead remained stable in size before regressing
with advancing gestation. This highlights some inherent
heterogeneity of growth patterns among prenatally diagnosed
lung malformations.
It has been suggested that the fetus eventually ‘grows around’
the tumor as the thoracic volume begins to increase relative
to overall somatic growth after 26weeks of gestation.11,22 Our
data suggest that after an initial size increase, what followed
in most lesions was a proportionate decline in the CVR
by 29weeks of gestation. However, given that overall fetal
lung volumes are known to increase relative to fetal head
circumference during the third trimester,23 the observed decline
in the size of CPAMs during this time period is unlikely to be
explained solely by changes in overall somatic growth. Mass
regression seems to correspond with the natural transition in
fetal embryology between the canalicular and saccular stages
of lung development. During this transition, investigators have
hypothesized that an asynchrony in epithelial–mesenchymal
interactions within CPAMs occurs, leading in alterations in
cell proliferation relative to apoptosis.24 Because bronchial
obstruction during early lung development may be an inciting
event in the disease pathogenesis of lung malformations,25,26
some have postulated that alleviation of a transient bronchial
mucous obstruction as the airways enlarge may also play a role
in lesion size reduction.27
In this study, the mean CVR at initial presentation was 0.51,
which is slightly lower than the mean initial CVR documented
elsewhere9,13,28 but comparable with that reported in another
study.8 Given that our lung lesions were, on average, small
and all had an initial CVR less than or equal to 1.6, close
longitudinal follow-up did not alter the prenatal management
in most fetuses. Nonetheless, we believe serial ultrasound data
were informative for several reasons. First, given the potential
for longitudinal growth of some lesions, the gestational age
when the CVR is measured and referred to tertiary care
providers has relevance in terms of the need for close follow-
up and accurate prognosis. We found that longitudinal
tracking of the CVR also identified several patients deemed
to be at increased risk for poorer outcomes. Second, we
have found these data are useful for giving evidence-based
information about the natural history of fetal lung lesions
to expectant parents during initial prenatal counseling
discussions.29 In approximately 90% of cases, the initial CVR
will be less than 1.0. We would suggest serial ultrasounds every
2weeks until evidence of CVR decline. In the majority of cases,
either stable size or unequivocal regression will be seen by
29weeks of gestation. Once the CVR has stabilized or begins
to regress, ultrasound surveillance can be individualized with
less frequent scanning.
A secondary objective of this study was to determine
whether the CVR was an accurate measure of mass size
when compared with postnatal CT scan, the current imaging
gold standard.30,31 Despite changes observed in CVR growth
over time, the initial, mean, maximum, and final CVRs
were all significantly correlated with postnatal CT lesion size
dimensions and likelihood for surgical resection. This data
further validate the CVR as a reliable, quantitative tool that
can be useful for predicting clinical outcomes after delivery.
However, reliance on the final CVR in isolation may lead
to a false negative diagnosis because some of these lesions
can become isoechoic, particularly late in gestation.32
In all asymptomatic prenatally diagnosed cases, it remains
imperative to image postnatally, preferrably by contrast-
enhanced CT scan, to further characterize any lesions if
preemptive surgical resection is being considered.33,34
Although the current series using prospectively collected
data has further elucidated the prenatal growth patterns
Figure 4 Relationship between prenatal congenital pulmonary
airway malformation volume ratio (CVR) and postnatal outcome
measures. (A) XY scatter plot showing relationship between mean
CVR and postnatal dimensions by computed tomography (CT) scan
(in cm). (B) Column bar graph of the mean CVR and standard error
of the mean in patients undergoing surgical resection versus
observation (the symbol ‘*’ denotes p< 0.05)
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oflung malformations, the study has some caveats and
limitations. This is a single institution retrospective study
based on prospectively collected data with stringent inclusion
criteria. All four fetuses that developed hydrops were
excluded because of late referral diagnosis (n = 2) or lack of
serial measurements (n = 2), which was a common cause for
exclusion before 2005. Furthermore, we acknowledge that
many centers do not routinely measure CVRs8 and that
obtaining an accurate CVR may involve a learning curve. Only
seven macrocystic lesions were evaluated, and there is data to
suggest that CPAMs with a dominant macrocyst may have
unpredictable growth rates.13 The involvement of multiple
maternal-fetal medicine providers may have allowed for
increased measurement error. Additionally, we studied the
full spectrum of lung malformations rather than restricting
our analysis to pathologically confirmed CPAM lesions. While
greater homogeneity of lung pathology would certainly be
ideal, there is a high discordance between prenatal and
postnatal diagnosis, particularly with respect to systemic
feeding vessels. Interestingly, the current study also shows
that BPS and other lesions have similar growth profiles
compared with CPAMs. We therefore find that such
pathologic distinctions are becoming increasingly irrelevant
from a fetal diagnosis and management perspective. Finally,
while many pediatric surgeons advocate for early surgical
resection for most asymptomatic lung malformations given
their long-term risk of complications, the threshold for
surgery is specific to each institution and continues to
evolve.35–37
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WHAT’S ALREADY KNOWN ABOUT THE TOPIC?
• The congenital pulmonary airway malformation volume ratio (CVR) is
a common prenatal ultrasound measure of relative mass size in
fetuses with lung malformations.
• The initial CVR and maximum CVR have been shown to be
predictive of hydrops and neonatal respiratory compromise,
respectively.
WHAT DOES THIS STUDY ADD?
• Gestational age is important when interpreting CVR measurements
because two thirds of lesions increase in size at 25–26weeks
before spontaneous involution occurs.
• The mean CVR correlates with size measured by postnatal
computed tomography scan.
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